Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PHLPP2 Antibodies:
anti-Mouse (Murine) PHLPP2 Antibodies:
anti-Rat (Rattus) PHLPP2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal PHLPP2 Primary Antibody for IP, WB - ABIN151321
Sangai, Akcakanat, Chen, Tarco, Wu, Do, Miller, Arteaga, Mills, Gonzalez-Angulo, Meric-Bernstam: Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. in Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Show all 2 Pubmed References
Human Polyclonal PHLPP2 Primary Antibody for ELISA, WB - ABIN253307
Gao, Furnari, Newton: PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. in Molecular cell 2005
Cheliensisin A (Chel A)treatment led to PH domain and Leucine rich repeat Protein (show NYX Antibodies) Phosphatases (PHLPP2) protein degradation and subsequently increased in c-Jun (show JUN Antibodies) phosphorylation, which could be attenuated by inhibition of autophagy mediated by Beclin 1 (show BECN1 Antibodies).
Results show that MiR (show MLXIP Antibodies)-27a directly targets PHLPP2 by binding to its 3'-UTR (show UTS2R Antibodies) to inhibit its expression, and that downregulation of PHLPP2 could rescue the effect of anti-miR (show MLXIP Antibodies)-27a in gastric cancer cells.
miR (show MLXIP Antibodies)-938 promoted CRC (show CALR Antibodies) cell proliferation by inhibiting PHLPP2
two PHLPP (show PHLPP1 Antibodies) isozymes, PHLPP1 (show PHLPP1 Antibodies) and PHLPP2, were identified in a search for phosphatases that dephosphorylate Akt (show AKT1 Antibodies), and thus suppress growth factor signaling.
results identify a novel role of PHLPP (show PHLPP1 Antibodies) in regulating aPKC and cell polarity.
Low PHLPP2 expression is associated with luminal breast cancer.
miR (show MLXIP Antibodies)-3117 contributes to the proliferation of HepG2 by targeting PHLPPL.
Overexpression of PHLPP2 without its 3'UTR (show UTS2R Antibodies) attenuated the effects of miR (show MLXIP Antibodies)-181a on cell proliferation and apoptosis in keloid fibroblast cells.
Suggest that direct PHLPP2 downregulation is required for miR (show MLXIP Antibodies)-32-induced cell proliferation of breast cancer cells.
Our studies not only first time identify PHLPP2 downregulation by lung carcinogen B[a]P/B[a]PDE (show ALDH7A1 Antibodies), but also elucidate a novel molecular mechanisms underlying lung inflammation and carcinogenesis upon B[a]P/B[a]PDE (show ALDH7A1 Antibodies) exposure.
KCTD17, which is up-regulated in liver tissues of obese mice and patients with NAFLD, binds to phosphorylated PHLPP2 to target it for ubiquitin-mediated degradation; this increases expression of genes that regulate lipogenesis to promote hepatic steatosis.
PHLPP (show PHLPP1 Antibodies) is a negative regulator of RAF1 (show RAF1 Antibodies), which reduces colorectal cancer cell motility and prevents tumor progression in mice.
Protein phosphatase that mediates dephosphorylation of 'Ser-473' of AKT1, 'Ser-660' of PRKCB isoform beta-II and 'Ser- 657' of PRKCA. AKT1 regulates the balance between cell survival and apoptosis through a cascade that primarily alters the function of transcription factors that regulate pro- and antiapoptotic genes. Dephosphorylation of 'Ser-473' of AKT1 triggers apoptosis and decreases cell proliferation. Also controls the phosphorylation of AKT3. Dephosphorylation of PRKCA and PRKCB leads to their destabilization and degradation. Inhibits cancer cell proliferation and may act as a tumor suppressor.
PH domain leucine-rich repeat-containing protein phosphatase 2
, PH domain and leucine rich repeat protein phosphatase 2
, PH domain leucine-rich repeat-containing protein phosphatase 2-like
, GTPase activating protein and VPS9 domains 1